Distribution of company announcements to the professional platforms, finance portals and syndication of important corporate news to a wide variety of news aggregators and financial news systems.
Navamedic ASA (OSL:NAVA) (Lysaker, Norway, 4 September 2008). A new study performed at Karolinska Institutet, Stockholm, demonstrates the efficacy of Naltrexone for the treatment of amphetamine dependence. Naltrexon Vitaflo, marketed by Navamedic's subsidiary Vitaflo Scandinavia, is the only naltrexone product in Sweden and Denmark.
There is currently no approved pharmacotherapy for amphetamine dependence. A study performed at Karolinska Institutet in Stockholm on 80 patients demonstrates that patients given naltrexone had a significantly higher number of amphetamine-negative urine samples compared with the placebo group. The study was published 2 September 2008 in the American Journal of Psychiatry.
Naltrexon Vitaflo is the only naltrexone product in Sweden and Denmark. Naltrexon Vitaflo is currently approved in the treatment of Alcohol abuse in Sweden and Finland and in the treatment of Heroine abuse in Denmark and Finland. Vitaflo Scandinavia has the rights to Naltrexon Vitaflo also in Norway, but the product is not registered.
Amphetamine is among the most common narcotics in all the Nordic countries. In Sweden it is the most commonly abused substance after alcohol and cannabis.
For more information about the study, please refer to - Naltrexone for the Treament of Amphetamine Dependence: A Randomized, Placebo-Controlled Trial, by Nitya Jayaram-Lindström, Andes Hammarberg, Olof Beck and Johan Franck (Am J Psychiatry Jayaram-Lindström et al.; AiA: 1-7)
For further information, please contact:
Øyvind W. Brekke, CEO Navamedic ASA E-mail: oyvind.brekke@navamedic.com Office: +47 67 11 25 40 Mobile: +47 91 19 81 64
Tina Sandström, Managing Director in Vitaflo Scandinavia AB E-mail: tina.sandstrom@vitaflo.net Office: +45 48 22 1838
